Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three vs Six Cycles of Adjuvant Chemotherapy for High-risk Retinoblastoma
NCT01906814Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2013
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, carboplatin and etoposide in retinoblastoma (Rb) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Disease-Free Survival at 5 years. Started Aug 2013; status: active, not recruiting.
02
Drugs
vincristinecarboplatinetoposide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT01906814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01906814.